Biblio
“Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 467-475, 2023.
, “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
, “Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial-The OmegAD Study.”, J Alzheimers Dis, vol. 83, no. 3, pp. 1291-1301, 2021.
, “Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels.”, J Alzheimers Dis, vol. 84, no. 1, pp. 119-128, 2021.
, “Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease.”, J Alzheimers Dis, vol. 83, no. 1, pp. 355-366, 2021.
, “Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1629-1642, 2021.
, “Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 77, no. 3, pp. 1353-1368, 2020.
, “Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-β Load.”, J Alzheimers Dis, vol. 76, no. 1, pp. 291-301, 2020.
, “Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 71, no. 1, pp. 281-290, 2019.
, “Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 3, pp. 775-783, 2019.
, “A 10-Year Follow-Up of Adiposity and Dementia in Swedish Adults Aged 70 Years and Older.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1325-1335, 2018.
, “Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants.”, J Alzheimers Dis, vol. 63, no. 2, pp. 479-487, 2018.
, “Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage.”, J Alzheimers Dis, vol. 62, no. 1, pp. 385-397, 2018.
, “Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type.”, J Alzheimers Dis, vol. 62, no. 1, pp. 417-427, 2018.
, “From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. s1, pp. S271-S279, 2018.
, “Induction of Amyloid-β42 Production by Fipronil and Other Pyrazole Insecticides.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1663-1681, 2018.
, “Low Cerebrospinal Fluid Aβ42 and Aβ40 are Related to White Matter Lesions in Cognitively Normal Elderly.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1877-1886, 2018.
, “The Past and the Future of Alzheimer's Disease Fluid Biomarkers.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1125-1140, 2018.
, “Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1857-1863, 2018.
, “S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.”, J Alzheimers Dis, vol. 64, no. 1, pp. 171-179, 2018.
, “Alterations in the Balance of Amyloid-β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1281-1291, 2017.
, “Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate.”, J Alzheimers Dis, vol. 58, no. 3, pp. 821-828, 2017.
, “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
, “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
, “Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1327-1334, 2017.
,